Absci (NASDAQ:ABSI) Announces Quarterly Earnings Results

Absci (NASDAQ:ABSI) posted its quarterly earnings results on Thursday. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.01, FiscalAI reports. The business had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $1.39 million. Absci had a negative return on equity of 64.66% and a negative net margin of 6,450.76%.

Here are the key takeaways from Absci’s conference call:

• ABS-201 is on track—blinded safety/tolerability/PK data from the SAD cohorts is expected next month, with an interim 13?week proof?of?concept readout in H2 2026 and a full 26?week POC in early 2027, and PK modeling supports roughly 2–3 injections over six months.
• Management projects a >$25 billion U.S. total available market for androgenetic alopecia and cites a target profile (~35 hairs/cm² similar to high?dose oral minoxidil) that could expand the market, but these figures are forward?looking and survey?based.
• The pipeline is expanding within prolactin biology with the addition of ABS-202, an anti?prolactin receptor antibody aimed at inflammatory/immune indications, signaling strategic focus on a franchise approach beyond AGA and endometriosis.
• Absci is de?emphasizing oncology and will stop internal funding for ABS?301 and ABS?501, narrowing therapeutic diversity and concentrating resources on ABS?201 and prolactin?focused programs.
• Financials show $125.7M in cash and marketable securities at March 31, 2026 with management saying runway into H1 2028, Q1 R&D spend rose to $19.3M, and the company is pursuing non?dilutive partnerships and AI?driven efficiency gains.

Absci Trading Up 2.6%

NASDAQ:ABSI opened at $5.90 on Friday. Absci has a 1-year low of $2.24 and a 1-year high of $6.24. The business’s 50-day moving average price is $3.29 and its two-hundred day moving average price is $3.31. The firm has a market capitalization of $917.16 million, a price-to-earnings ratio of -7.11 and a beta of 2.36.

Insiders Place Their Bets

In related news, insider Andreas Busch bought 100,000 shares of the business’s stock in a transaction on Thursday, March 12th. The shares were purchased at an average price of $2.29 per share, with a total value of $229,000.00. Following the completion of the purchase, the insider owned 421,446 shares of the company’s stock, valued at $965,111.34. This represents a 31.11% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 10.49% of the company’s stock.

Hedge Funds Weigh In On Absci

Hedge funds have recently added to or reduced their stakes in the stock. ARK Investment Management LLC raised its holdings in Absci by 3.2% in the fourth quarter. ARK Investment Management LLC now owns 12,550,799 shares of the company’s stock worth $43,802,000 after purchasing an additional 388,026 shares during the period. Vanguard Group Inc. raised its position in shares of Absci by 12.9% during the third quarter. Vanguard Group Inc. now owns 7,281,918 shares of the company’s stock worth $22,137,000 after purchasing an additional 830,336 shares during the period. State Street Corp raised its position in shares of Absci by 190.1% during the fourth quarter. State Street Corp now owns 5,990,877 shares of the company’s stock worth $20,908,000 after purchasing an additional 3,925,926 shares during the period. Geode Capital Management LLC raised its holdings in shares of Absci by 6.1% during the fourth quarter. Geode Capital Management LLC now owns 3,239,623 shares of the company’s stock worth $11,309,000 after acquiring an additional 186,708 shares during the period. Finally, Ameriprise Financial Inc. raised its holdings in shares of Absci by 24.4% during the third quarter. Ameriprise Financial Inc. now owns 3,191,011 shares of the company’s stock worth $9,701,000 after acquiring an additional 625,451 shares during the period. Institutional investors and hedge funds own 52.05% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on ABSI. Weiss Ratings reiterated a “sell (d-)” rating on shares of Absci in a report on Monday, April 20th. Needham & Company LLC reiterated a “buy” rating and issued a $7.00 price target on shares of Absci in a report on Wednesday, March 25th. Finally, Truist Financial raised their price target on Absci from $9.00 to $11.00 and gave the company a “buy” rating in a report on Friday. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Absci currently has an average rating of “Moderate Buy” and an average target price of $7.58.

Absci News Roundup

Here are the key news stories impacting Absci this week:

• Positive Sentiment: Truist Financial raised its price target on Absci from $9 to $11 and reiterated a buy rating, signaling increased confidence in the stock’s upside. Benzinga article
• Positive Sentiment: Absci reported first-quarter EPS of -$0.19, slightly better than the consensus estimate of -$0.20, showing modest earnings improvement versus expectations. MarketBeat earnings report
• Positive Sentiment: The company said it successfully dosed all four planned healthy-volunteer cohorts in its ABS-201 HEADLINE trial, reported favorable emerging safety data, and advanced dosing in the next cohort, which supports progress in its lead program. GlobeNewswire article
• Neutral Sentiment: Absci also expanded its prolactin pipeline with ABS-202, adding another internal program, but this is still early-stage and may take time to influence fundamentals. GlobeNewswire article
• Negative Sentiment: Revenue came in well below analyst expectations, highlighting that the company remains in an early, pre-commercial stage with limited near-term sales traction. Zacks article

Absci Company Profile

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.